drug pricing

  • |

    Public Cancer Research, Private Cancer Profits: The Taxpayer Paid Twice

    ByPhil McCracken

    I followed the Taxol invoice, and the handwriting gets suspiciously fancy near the bottom. Publicly supported NIH research helped carry the scientific risk behind paclitaxel, while Bristol Myers Squibb became the name attached to the commercial blockbuster. The exact accounting deserves careful checking, but the central complaint is hard to miss: shared research can become private revenue before the public gets a meaningful return.

    That is the pharmaceutical business model in a lab coat. Taxpayers help finance the runway, private interests get the applause, and patients are handed the receipt for progress they helped make possible. Nobody objects to a company earning money by bringing a treatment to patients; the question is why public investment so often exits through the front door while public accountability is left waiting in the lobby. Follow the invoice long enough and “research for all” can end with profits for the private and a second bill for the sick.

  • |

    The Drug Pricing Rule Has a Lobbyist in the Back Seat

    ByPhil McCracken

    I look at Washington’s healthcare paperwork the way a diner waitress looks at a fake coupon: polite, tired, and already hunting for the fine print. CMS is considering a proposed Medicare rule that could treat certain fixed-combination drugs as the same qualifying single-source drug as an originator medicine for price negotiation. Patients may see one prescription. The policy question is whether Washington sees one product—or several convenient identities parked under the same hood.

    CMS issued the proposal June 12, set an August 17 comment deadline, and is expected to finalize it in fall 2026. That makes this less a chemistry quiz than a money-trail dispute. If a combination product remains legally separate from the medicine it combines, more revenue could remain outside the negotiation process. That is not proof anyone designed the product as an escape hatch. It is the practical question sitting on the counter while everyone argues about labels.

    Inside Health Policy reported that biologics manufacturers objected to CMS’s approach, arguing that separate FDA categories raise legal-authority and innovation concerns. Those are serious arguments, and agencies should not smuggle major policy changes through a filing cabinet labeled “technical clarification.” But the industry’s preferred separation also has a financial consequence: separate categories can mean separate treatment when Medicare decides what qualifies for negotiation.

    This is where the fine print starts wearing donor perfume. The public argument is about innovation, regulatory boundaries, and whether CMS has gone too far. The money question is simpler: who benefits if the category stays split? Manufacturers may preserve separate revenue streams from negotiated pricing, while patients and taxpayers are left to admire the elegance of the classification system from the payment window.

    At the pharmacy drive-through, nobody orders “one originator medicine with a regulatory garnish.” They get a prescription. In Washington, however, one prescription can be asked to produce two billing identities, two receipts, and two opportunities to keep the negotiated-price window closed. The rule is still proposed, the dispute is still active, and the invoice has not finished crawling out from under the lobbyist’s coat. But the public should know what this technical fight can decide: whether a medicine’s category serves patients—or protects the revenue attached to it.

    Sources

  • |

    Public Science, Private Checkout

    ByHarlan Quill

    I keep a library card and a calculator nearby for moments like this: taxpayers help fund NIH and university research, then meet the finished medicine at the pharmacy counter priced like a used county courthouse. Not every treatment follows that exact route, and public research can benefit everyone. But when public money absorbs much of the early risk while private companies control the patent and the price, the arrangement deserves more than a ceremonial ribbon cutting.

    The institutional math is remarkably tidy. Public laboratories supply knowledge, universities supply talent, investors celebrate the next big product, and patients receive the portion marked “due now.” That is not necessarily unlawful; it is simply a system with impressive machinery for privatizing the upside and outsourcing the bill. A sensible public investment should purchase public leverage, affordable access, or both. Otherwise taxpayers sponsored discovery, investors collected the dividend, and patients were assigned to crowd-fund the receipt.

  • |

    The Public Helped Prove Remdesivir—Then Got the Invoice

    ByPhil McCracken

    I follow the invoice, and Remdesivir leads straight to the strangest line item in pandemic economics: public support helping carry the research risk while Gilead’s approximately $3,120 list-price headline arrives like the taxpayer has never met the taxpayer. That figure was not necessarily every patient’s final bill, and public funding did not pay for every step of the work. But the fairness problem remains plain: when public money helps steady the ladder, private billing should not act like it built the building alone.

    America gets cast as both venture capitalist and customer—asked to help finance the uncertain part, then sent shopping at the counter once the emergency treatment is ready. The money trail wore cologne, but the receipt still smells like a double charge: first as research backer, then as buyer. If public science helps make a medical breakthrough possible, why does the public receive so little leverage over the price and so much responsibility for paying it?

  • |

    Public Grants, Private Tollbooth: Who Pays Twice for Xtandi?

    ByPhil McCracken

    At my invoice desk, the Xtandi money trail arrives wearing a lab coat and leaves in a limousine. The complaint is straightforward: public funding helped support UCLA-linked research, while commercialization and patent control became associated with Astellas and Pfizer. Then patients encountered annual U.S. price claims reaching roughly $160,000 to $180,000. That is a remarkable billing arrangement—taxpayers help finance the road, private interests control the toll gate, and the patient gets charged for driving on it.

    Not every stage of Xtandi’s development can be reduced to one public grant or one private decision, and a list price is not the same as every patient’s bill. But the public-return question remains as stubborn as a bad line item: when public science helps move an essential medicine forward, what does the public receive besides another invoice? Innovation may begin as public service, yet somehow ends as private property with a collections department. Follow the invoice long enough and it reaches the same destination: the patient, standing at the pharmacy counter with the receipt and no lobbyist’s expense account.

  • |

    We Fund the Science. They Set the $3.95 Million Price.

    ByPhil McCracken

    I followed the Kebilidi invoice and found NIH’s NCATS on the public-science side, PTC Therapeutics at the commercial finish line, and a stated price of $3.95 million waiting like it had its own congressional parking space. That does not mean public research invented every molecule or erased the company’s costs. It does mean taxpayers and patients deserve a seat at the pricing table when public support helped move a rare-disease therapy from scientific risk toward treatment.

    One-time gene therapies are complex and expensive; nobody is asking the lab to accept payment in inspirational refrigerator magnets. But complexity cannot be the magic word that makes public investment disappear from the conversation. The public helped build the runway, while private billing arrived dressed as the sole owner of aviation. Follow the invoice: government may not have created every part of Kebilidi, but families should not be treated like silent partners who receive only the receipt. Fair pricing and fair taxes are the minimum decent terms.

  • |

    The Miracle Arrives With a $3.2 Million Invoice

    ByPhil McCracken

    Here is the money trail presented by the scenario: children’s-hospital and academic micro-dystrophin research tied to Nationwide Children’s Hospital moves into Sarepta’s private commercialization pipeline, and the number waiting at the end is $3.2 million. Nationwide is presented as receiving licensing and royalty revenue; families and payers are presented as facing the cost. That is a remarkable invoice-routing system: the science gets described as a shared triumph, while the people who need it are treated like they wandered into the pricing meeting without a badge.

    Profit is not the villain. Pretending the public-private pipeline ends at “innovation” is. If the figure and licensing arrangement are accurate as presented, the contradiction is hard to miss: the breakthrough gets inspirational music, the commercial deal gets revenue, and the family gets a financial document written in the ancient language of “please indicate which organ you’d like to sell first.” Nobody has to oppose useful medicine or licensing to ask why the people carrying the medical and financial risk get no meaningful seat at the pricing table.

  • |

    Skysona and the $3 Million Toll Booth

    ByPhil McCracken

    I audit public-private invoices for a living, and Skysona arrives looking like a federal infrastructure project with a very expensive toll booth. The premise is straightforward: NIH support, academic medical centers, and basic research helped build the gene-therapy road, while bluebird bio brought a finished treatment to market with a $3 million price tag. Rare-disease therapies are complex, and private development matters. Fine. Complexity is not a magic eraser for the public role.

    The money trail deserves more than an innovation ribbon-cutting. If taxpayers and public institutions carried part of the long, uncertain research burden, patients and families are entitled to ask what public return comes with the private invoice. Nobody is claiming bluebird bio did nothing; the question is who absorbed the early risk and who gets the reward when science becomes a product. Taxpayers helped pave the road. Calling the toll booth innovation does not make the receipt disappear.

  • |

    Tiny Tweak, New Monopoly: Evergreening Shouldn’t Mean a Bigger Bill

    ByJustin Jest

    I’m not saying the billion-dollar backroom worships a stopwatch, but the patent expires and—boom—“innovation” shows up as an extended-release, a new coating, or a combo pill. Same original drug, new paperwork, new dose, with that fresh little seal slapped on like it’s a brand-new invention. Not every reformulation is a real breakthrough; sometimes it’s just the legal version of swapping a street sign and calling it “progress.”

    When competition waits, Medicare keeps paying while the price clock does a victory lap under a new nameplate. A small change shouldn’t mean a bigger bill—yet the system treats “tiny tweak” like it’s the next chapter in monopoly fanfic, just with higher invoices.

  • |

    The $4.25 Million Pill: Public Science, Private Profit, and Pricey Pills

    ByMoses Pray

    Brothers and sisters, gather ’round the altar of irony where we find our taxpayer dollars funding drug research like manna from a public lab, only for the private sector to charge us $4.25 million a pill for the privilege of survival. It seems we’ve turned public good into a golden calf of profit, where sacred dollars offered in good faith find themselves on a pharmacy shelf with a price tag only the angels can afford.

    Is this what stewardship looks like? We bake a cake with ingredients from our own pantry, then pay $50 a slice just to enjoy what was ours to begin with. Perhaps it’s time we reconsider who truly deserves that spot in the front pew—charity or commerce—and whether public funding ought to serve the public purse rather than padding the pockets of a few blessed businessmen. Peace be with you, unless of course, you’re the one holding the receipt.

End of content

End of content